立高食品(300973.SZ):擬推2021年股票期權激勵計劃
格隆匯7月30日丨立高食品(300973.SZ)公佈2021年股票期權激勵計劃(草案),此激勵計劃採用的激勵工具為股票期權。股票來源為公司自二級市場回購或定向增發公司A股普通股股票。
此激勵計劃擬授予的股票期權數量為850.00萬份,約佔此激勵計劃草案公吿時公司股本總額的5.02%。行權價格為108.20元/股。
此激勵計劃授予的激勵對象不超過9人,包括公司董事、高級管理人員以及公司(含子公司)其他核心管理人員,不包括公司獨立董事和監事。有效期為自股票期權授予日起至全部行權或註銷之日止,最長不超過72個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.